ORAL ABSTRACT SESSION
Melanoma/Skin Cancers
Mon, Jun 06 • 1:15 PM - 4:15 PM
Location: Arie Crown TheaterAbstract 9500 Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma.
Interesting to note that patients with prior immune therapy had better response than the ones who started on MEK inhibitor.
So unfortunately, not really great news for patients with NRAS mutant Melanoma:
Abstract 9501 A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
UPDATE ON COMBI-D
Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma.
1:39 PM - 1:51 PM
Abstract 9502
Keith Flaherty, MD
Good overview over targeted therapy:
And again- patients with lower LDH do better-
Three-year overall survival for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.
2:15 PM - 2:27 PM
Abstract 9503
Caroline Robert, MD, PhD - Presenter • Disclosure Gustave Roussy and Paris-Sud University
most important take-home message: most patients with complete response continue to respond even after stopping treatment
A very nice write-up from ASCO can be found here.
Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.
2:27 PM - 2:39 PM
Abstract 9504
Jacob Schachter, Prof, MD - Presenter • Disclosure
Ella Institute for Research and Treatment of Melanoma, Sheba Medical Center
Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort.
2:51 PM - 3:03 PM
Abstract 9506
Georgina V. Long, BSc, PhD, MBBS, FRACP - Presenter • Disclosure
Melanoma Institute Australia, The University of Sydney, Mater Hospital, and Royal North Shore Hospital
No comments:
Post a Comment